Gilead Sciences (GILD) has been drawing investor attention despite the market fluctuations. As the company continuously ascends, GILD showcases resilience, providing value for long-term shareholders. Potential challenges, such as controversies over HIV franchise and possible cuts in HIV prevention, have pressured the stock. But its performance remains competitive against other medical peers. The already strong Q4 earnings are accompanied by an increase in dividend to $0.79, bringing GILD near its 52-week high. Meanwhile, the optimism surrounding the company continues as it presents first clinical data for Lenacapavir, an investigational once-yearly drug for HIV prevention. GILD tops Q4 earnings and revenue estimates with strong growth in HIV and Oncology, boding well for 2025 outlook. This robust performance triggered several upgrades from major financial institutions, but concerns over cuts in HIV prevention spending tempers some of the enthusiasm. At the same time, several analysts and hedge funds view the stock as undervalued and a top dividend stock, suggesting possible future growth.
